Genmab Announces Approval Of TIVDAK In Japan - Quick Facts

(RTTNews) - Genmab A/S (GMAB) announced that the Japan Ministry of Health, Labour and Welfare has approved TIVDAK for the treatment of advanced or recurrent cervical cancer that has progressed on or after cancer chemotherapy. The company noted that TIVDAK is the first and only ADC to be approved for people living with cervical cancer in Japan.

Judith Klimovsky, Chief Development Officer of Genmab, said: "This approval marks an important step forward in transforming the treatment paradigm in Japan, ultimately bringing new hope and possibility to patients and their loved ones."

For More Such Health News, visit rttnews.com.